vs
ICON PLC（ICLR）与MAXCYTE, INC.（MXCT）财务数据对比。点击上方公司名可切换其他公司
ICON PLC的季度营收约是MAXCYTE, INC.的426.7倍（$2.0B vs $4.8M）。ICON PLC净利率更高（0.1% vs -200.5%，领先200.6%）。ICON PLC同比增速更快（0.6% vs -20.9%）。ICON PLC自由现金流更多（$333.9M vs $-2.9M）。过去两年ICON PLC的营收复合增速更高（0.6% vs -7.4%）
ICON plc是总部位于爱尔兰的跨国医疗智能与临床研究服务机构，专注为全球医药健康领域客户提供专业研究及情报支持，截至2025年2月，已在全球55个国家布局业务，员工规模约4.19万人。
MaxCyte Inc.是一家全球化生物技术企业，专注于开发细胞工程平台及细胞与基因治疗领域的赋能技术。其专利非病毒细胞修饰系统被制药、生物技术及生命科学研究机构广泛采用，支持免疫疗法、基因编辑疗法及下一代生物药从临床前到商业化的全流程研发。
ICLR vs MXCT — 直观对比
营收规模更大
ICLR
是对方的426.7倍
$4.8M
营收增速更快
ICLR
高出21.6%
-20.9%
净利率更高
ICLR
高出200.6%
-200.5%
自由现金流更多
ICLR
多$336.8M
$-2.9M
两年增速更快
ICLR
近两年复合增速
-7.4%
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $2.0B | $4.8M |
| 净利润 | $2.4M | $-9.6M |
| 毛利率 | — | — |
| 营业利润率 | 4.2% | -234.5% |
| 净利率 | 0.1% | -200.5% |
| 营收同比 | 0.6% | -20.9% |
| 净利润同比 | -98.8% | 9.4% |
| 每股收益（稀释后） | $0.03 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICLRMXCT
| Q4 25 | — | $4.8M | ||
| Q3 25 | $2.0B | $4.6M | ||
| Q2 25 | $2.0B | $5.8M | ||
| Q1 25 | $2.0B | $5.7M | ||
| Q4 24 | — | $6.1M | ||
| Q3 24 | $2.0B | $5.6M | ||
| Q2 24 | $2.1B | $5.0M | ||
| Q1 24 | $2.1B | $5.6M |
净利润ICLRMXCT
| Q4 25 | — | $-9.6M | ||
| Q3 25 | $2.4M | $-12.4M | ||
| Q2 25 | $183.0M | $-12.4M | ||
| Q1 25 | $154.2M | $-10.3M | ||
| Q4 24 | — | $-10.6M | ||
| Q3 24 | $197.1M | $-11.6M | ||
| Q2 24 | $146.9M | $-9.4M | ||
| Q1 24 | $187.4M | $-9.5M |
营业利润率ICLRMXCT
| Q4 25 | — | -234.5% | ||
| Q3 25 | 4.2% | -307.4% | ||
| Q2 25 | 10.4% | -244.3% | ||
| Q1 25 | 11.0% | -214.1% | ||
| Q4 24 | — | -213.1% | ||
| Q3 24 | 14.1% | -250.4% | ||
| Q2 24 | 10.8% | -241.0% | ||
| Q1 24 | 13.7% | -219.8% |
净利率ICLRMXCT
| Q4 25 | — | -200.5% | ||
| Q3 25 | 0.1% | -269.7% | ||
| Q2 25 | 9.1% | -212.2% | ||
| Q1 25 | 7.7% | -178.7% | ||
| Q4 24 | — | -175.0% | ||
| Q3 24 | 9.7% | -205.9% | ||
| Q2 24 | 6.9% | -188.8% | ||
| Q1 24 | 9.0% | -170.6% |
每股收益（稀释后）ICLRMXCT
| Q4 25 | — | — | ||
| Q3 25 | $0.03 | $-0.12 | ||
| Q2 25 | $2.30 | $-0.12 | ||
| Q1 25 | $1.90 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.36 | $-0.11 | ||
| Q2 24 | $1.76 | $-0.09 | ||
| Q1 24 | $2.25 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $468.9M | $103.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $9.3B | $171.5M |
| 总资产 | $16.5B | $202.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ICLRMXCT
| Q4 25 | — | $103.0M | ||
| Q3 25 | $468.9M | $105.7M | ||
| Q2 25 | $390.4M | $126.6M | ||
| Q1 25 | $526.7M | $138.3M | ||
| Q4 24 | — | $154.5M | ||
| Q3 24 | $695.5M | $153.8M | ||
| Q2 24 | $506.6M | $157.3M | ||
| Q1 24 | $396.1M | $157.5M |
股东权益ICLRMXCT
| Q4 25 | — | $171.5M | ||
| Q3 25 | $9.3B | $180.3M | ||
| Q2 25 | $9.6B | $190.7M | ||
| Q1 25 | $9.5B | $199.4M | ||
| Q4 24 | — | $206.3M | ||
| Q3 24 | $9.8B | $213.3M | ||
| Q2 24 | $9.6B | $221.3M | ||
| Q1 24 | $9.4B | $226.4M |
总资产ICLRMXCT
| Q4 25 | — | $202.5M | ||
| Q3 25 | $16.5B | $213.5M | ||
| Q2 25 | $16.6B | $219.8M | ||
| Q1 25 | $16.7B | $230.0M | ||
| Q4 24 | — | $239.5M | ||
| Q3 24 | $17.2B | $248.6M | ||
| Q2 24 | $17.0B | $251.5M | ||
| Q1 24 | $17.0B | $257.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $387.6M | $-2.7M |
| 自由现金流经营现金流 - 资本支出 | $333.9M | $-2.9M |
| 自由现金流率自由现金流/营收 | 16.3% | -61.0% |
| 资本支出强度资本支出/营收 | 2.6% | 4.8% |
| 现金转化率经营现金流/净利润 | 164.59× | — |
| 过去12个月自由现金流最近4个季度 | $1.0B | $-36.2M |
8季度趋势，按日历期对齐
经营现金流ICLRMXCT
| Q4 25 | — | $-2.7M | ||
| Q3 25 | $387.6M | $-7.5M | ||
| Q2 25 | $146.2M | $-9.9M | ||
| Q1 25 | $268.2M | $-14.4M | ||
| Q4 24 | — | $-7.8M | ||
| Q3 24 | $402.7M | $-4.4M | ||
| Q2 24 | $218.6M | $-4.8M | ||
| Q1 24 | $327.1M | $-10.6M |
自由现金流ICLRMXCT
| Q4 25 | — | $-2.9M | ||
| Q3 25 | $333.9M | $-7.8M | ||
| Q2 25 | $113.9M | $-10.4M | ||
| Q1 25 | $239.3M | $-15.1M | ||
| Q4 24 | — | $-8.0M | ||
| Q3 24 | $359.3M | $-4.8M | ||
| Q2 24 | $182.3M | $-5.1M | ||
| Q1 24 | $299.9M | $-11.4M |
自由现金流率ICLRMXCT
| Q4 25 | — | -61.0% | ||
| Q3 25 | 16.3% | -168.5% | ||
| Q2 25 | 5.6% | -179.2% | ||
| Q1 25 | 12.0% | -262.3% | ||
| Q4 24 | — | -131.6% | ||
| Q3 24 | 17.7% | -85.5% | ||
| Q2 24 | 8.6% | -103.3% | ||
| Q1 24 | 14.3% | -203.6% |
资本支出强度ICLRMXCT
| Q4 25 | — | 4.8% | ||
| Q3 25 | 2.6% | 6.5% | ||
| Q2 25 | 1.6% | 10.0% | ||
| Q1 25 | 1.4% | 11.4% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | 2.1% | 7.2% | ||
| Q2 24 | 1.7% | 5.9% | ||
| Q1 24 | 1.3% | 14.4% |
现金转化率ICLRMXCT
| Q4 25 | — | — | ||
| Q3 25 | 164.59× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 1.74× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.04× | — | ||
| Q2 24 | 1.49× | — | ||
| Q1 24 | 1.74× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICLR
| Other Customers | $681.3M | 33% |
| Clients1125 | $549.4M | 27% |
| Clients15 | $503.3M | 25% |
| Clients610 | $308.8M | 15% |
MXCT
暂无分部数据
